Market launch of the TetraGraph Viewer

 "In response to market demands for digital solutions to view patient data and trends - without complicated interfaces – we have developed the TetraGraph Viewer as a novel tool for better understanding and documenting the patient’s clinical data. This is yet another major leap for Senzime on the digital path to help reduce complications following surgery.” says Pia Renaudin, CEO of Senzime AB.

The TetraGraph Viewer will be released to end users through Senzimes distributors and sales partners in the respective regions.  

For further information, please contact : 

Pia Renaudin, CEO of Senzime AB                                                                                                           

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com       

TO THE EDITORS 

About Senzime 

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on March 26, 2019 08:45.